| 2004 | Lack of Correlation Between P-glycoprotein and Chemotherapy Resistance in Nasal NK/T-cell Lymphomas | LEUKEMIA & LYMPHOMA |
| 2015 | LAMC2 enhances the metastatic potential of lung adenocarcinoma | CELL DEATH AND DIFFERENTIATION |
| 2019 | Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients
| Cancer Research and Treatment |
| 2016 | Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2014 | Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2001 | Leptomeningeal Carcinomatosis in Solid Tumors ; Clinical Manifestation and Treatment
| Journal of the Korean Cancer Association (대한암학회지) |
| 2006 | Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports
| CANCER RESEARCH AND TREATMENT |
| 2021 | MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
| FUTURE ONCOLOGY |
| 2019 | Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
| FUTURE ONCOLOGY |
| 2022 | Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A | ESMO OPEN |
| 2018 | Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial | ANNALS OF SURGICAL ONCOLOGY |
| 2013 | Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer
| JOURNAL OF RADIATION RESEARCH |
| 1998 | Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE |
| 2019 | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer | ONCOLOGIST |
| 2018 | MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis. | JOURNAL OF SURGICAL ONCOLOGY |
| 2012 | Methylation status of lamin A/C in gastric cancer cell lines | HEPATO-GASTROENTEROLOGY |
| 2011 | MMP-2 as a putative biomarker for carcinomatosis in gastric cancer | HEPATO-GASTROENTEROLOGY |
| 2004 | MN/CA9 촉진자를 가진 replication-competent 아데노바이러스를 이용한 신세포암에 대한 종양 특이적 유전자요법
| KOREAN JOURNAL OF UROLOGY |
| 2008 | Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer | CANCER LETTERS |
| 1999 | Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer | International Journal of Molecular Medicine |
| 2017 | Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines | BIOCHEMICAL PHARMACOLOGY |
| 2007 | Molecular basis of the differences between normal and tumor tissues of gastric cancer | BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE |
| 2021 | Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses | HEPATOLOGY |
| 2021 | Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
| ANNALS OF ONCOLOGY |
| 2023 | Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
| YONSEI MEDICAL JOURNAL |
| 2001 | Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer | CANCER LETTERS |
| 2022 | MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress | JOURNAL OF CLINICAL ONCOLOGY |
| 2007 | Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
| ONCOLOGIST |
| 2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2005 | Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
| ANNALS OF ONCOLOGY |
| 2016 | Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
| ONCOTARGET |
| 2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET |
| 2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
| GASTRIC CANCER |
| 2022 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2007 | Novel and simple transformation algorithm for combining microarray data sets
| BMC BIOINFORMATICS |
| 2008 | Novel biomarker candidates for gastric cancer | ONCOLOGY REPORTS |
| 2023 | Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
| SCIENTIFIC REPORTS |
| 2009 | Oncogenic pathway combinations predict clinical prognosis in gastric cancer
| PLOS GENETICS |
| 2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I | MOLECULAR CANCER THERAPEUTICS |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2010 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 1996 | Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain | ONCOLOGY |
| 2012 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
| PLOS ONE |
| 1996 | P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer
| YONSEI MEDICAL JOURNAL |
| 1997 | P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2021 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer | BIOCHEMICAL PHARMACOLOGY |
| 1998 | p53 유전자 변형이 발생한 위암세포주에서 유전자이상 교정에 의한 항암제 감수성 변화
| Journal of the Korean Cancer Association (대한암학회지) |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2022 | PD-L1 expression and overall survival in Asian and western patients with gastric cancer | FUTURE ONCOLOGY |
| 2020 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies | JOURNAL OF THORACIC ONCOLOGY |
| 2019 | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
| Gastric Cancer |
| 2016 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | LANCET ONCOLOGY |
| 2018 | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
| CANCER SCIENCE |
| 2023 | Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial | LANCET |
| 2018 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | LANCET |
| 2022 | Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
